Diana Campelo Delgado,  —

Vaccines against COVID-19 appear to be safe and well-tolerated in patients with Dravet syndrome, a U.K. survey indicates. A brief report on the survey’s top results was announced recently by Dravet Syndrome UK. The COVID-19 pandemic has had an incalculable impact across the world. Recently, several…

After its approval in Europe in December, Fintepla (fenuramine) now is  commercially available in Germany as an add-on treatment for seizures associated with Dravet syndrome in patients 2 and older, the therapy’s developer, Zogenix, recently announced. “With the launch of FINTEPLA in Germany, physicians and caregivers here…

Tevard Biosciences and Zogenix announced entering a collaboration agreement to advance potential gene therapies for genetic epilepsies, including Dravet syndrome. “We are pleased to announce our collaboration with Zogenix, whose commitment to developing new treatments for Dravet syndrome and other genetic epilepsies is unparalleled,” Daniel Fischer, co-founder,…

Zogenix’s Fintepla (fenfluramine) has been approved by the European Commission (EC) as an add-on treatment for seizures associated with Dravet syndrome in patients ages 2 and older. With this decision, Zogenix will be able to market Fintepla in all European Union (EU) member states, plus the United Kingdom,…